SIGNAL - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn more about the role that a hormone called glucagon plays in controlling blood glucose levels. We want to know how it might influence sensitivity to insulin, which can change due to conditions like obesity and diabetes. By learning more about glucagon's relationship with insulin and blood sugar, we hope to find better ways to manage and treat diabetes.
Blood Glucose Control in Healthy Volunteers
Who Can Participate in the Study?
Adults ages 18-45 who:
- Are in good general health
- Have a body mass index (BMI) that is less than 27.0
- Have no personal history of diabetes or pancreatitis
- Do not have any first-degree family members (parents or siblings) who have type 1 diabetes
- Are not pregnant
For more information about who can join this study, contact the study team at kelsey.belski@duke.edu.
What is Involved?
If you choose to join this study and are found to be eligible, we will schedule you to complete 2 - 4 testing visits in the morning after an overnight fast.
During these testing visits, you will have an IV placed in each arm - one to draw blood samples at different times, and the other to infuse the study drugs. The study drugs include a saline (salt water) solution with a glucose tracer, insulin, glucose, and a synthetic form of glucagon. The glucose tracer is a nonradioactive form of hydrogen that marks the glucose given by IV to differentiate it from the glucose made in your body. The tracer is considered "investigational", which means the FDA has approved it for use in research. Participation in the study will last approximately 5-to-12 weeks.
Study Details
